---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-038756"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:11:50.080934+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics Q1 net loss $11.1M; cash runway into 2026 after $42M private placement

## Summary
- Q1 net loss $11.1M ($0.97/sh) vs $9.0M ($0.80/sh) YoY; R&D spend rose to $7.7M from $5.1M.
- Cash, equivalents and marketable securities $55.2M at Mar 31, 2024; combined with $42M net from April PIPE funds operations into 2026.
- TARA-002 in NMIBC: 3-month CR rate 38% overall; 63% in CIS-only; no Grade 3+ related AEs.
- ADVANCED-2 interim data (BCG-unresponsive/naïve) expected 2H 2024; registrational path aligned with FDA guidance.
- FDA aligned on registrational path for IV Choline Chloride as choline source for PN-dependent patients.

## SEC filing metadata
- accession: 0001213900-24-038756
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390024038756/0001213900-24-038756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390024038756/ea0204875-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-038756
- JSON: https://secwatch.observer/filing/0001213900-24-038756.json
- Plain text: https://secwatch.observer/filing/0001213900-24-038756.txt

## Key facts
- Earnings Releases
  Protara Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 2, 2024, Protara Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390024038756/0001213900-24-038756-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.